ImmuCell Corporation reported preliminary second-quarter total product sales of $7.2 million, an 11.55% increase from $6.4 million a year earlier, driven by its TriShield First Defense product. Domestic sales rose 27.7% to $6.2 million, while international sales fell 38.9% to $1 million. TriShield First Defense, used to prevent scours in newborn calves, generated $4.9 million in product sales, up 8.3% from $4.5 million in the prior-year quarter. For the six months ended June 30, 2026, total product sales climbed 20.9% to $17.5 million from $14.5 million in the same period last year.
ImmuCell CorporationTriShield First Defense product sales grew 8.3% and total sales rose 11.55%.